Webcast CME

Biologic Therapies Summit X and Vasculitis online series

Key Issues in the Differential Diagnosis of Vasculitis

Release date: July 13, 2023
Expiration date: July 12, 2025

Estimated Time of Completion: 1 hour and 45 minutes

Session agenda:
IgG4 Related Disease
Zachary Wallace, MD, MSc, Massachusetts General Hospital

Relapsing Polychondritis
Marcela Ferrada, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Vascular Ehlers-Danlos Syndrome
Adam Brown, MD, Cleveland Clinic

Drug-Induced Vasculitis
Kinanah Yaseen, MD, Cleveland Clinic

Description

Watch Biologic Therapies Summit X and Vasculitis Online Series, on-demand, complimentary webcasts that brings together world leaders in immune-based therapies to address cutting-edge topics in immunology and rheumatology. Education focuses on vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis. In addition, the online series features talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. A deep dive into rheumatoid arthritis, AS, PsA and SpA, infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. Lastly, the CE-certified webcasts address pain management and the exploration of the social and scientific fundamentals of pain.

 

Learning Objectives

  • Review the epidemiology and manifestations of IgG4-related disease.
  • Discuss the approach to diagnosis of IgG4-related disease.
  • Identify challenges in distinguishing IgG4-related disease from systemic vasculitis.
  • Review relapsing polychondritis and key issues in the differential diagnosis.
  • Highlight collagen and elastin, the matrix of blood vessels, COL3A1, and clinical manifestations of vascular EDS.
  • Describe the most common drugs associated with vasculitides
  • Review the differences between primary vasculitides and drug-induced vasculitis (DIV), and describe the management and prognosis of DIV.

Target Audience

The online series is directed to rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians / American Medical Association (AMA)
Cleveland Clinic Foundation Center for Continuing Education designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Nurses / American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 1.75 ANCC contact hours.

Physician Assistants / American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Credit
This activity was planned by and for the healthcare team, and learners will receive 1.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

Activity Director and Faculty

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair of Rheumatology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Carol Langford, MD, MHS
Director, Center for Vasculitis Care and Research
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Planning Committee

Cassandra Calabrese, DO
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Elizabeth (Betsy) Kirchner, DNP
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Amanda Mixon, PA-C
UCHealth Rheumatology Clinic - Harmony Campus
University of Colorado Health
Fort Collins, CO

Faculty

Adam Brown, MD
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Marcela Ferrada, MD
Staff Clinician, Vasculitis Translational Research Program
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Bethesda, MD

Zachary Wallace, MD, MSc
Division of Rheumatology, Allergy, and Immunology
Massachusetts General Hospital
Boston, MA

Kinanah Yaseen, MD
Department of Rheumatologic and Immunologic Disease
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

Adam Brown, MD

Amgen, Chemocentryx

Consulting
Teaching and Speaking
Cassandra Calabrese, DO

Astra Zeneca, Lilly

Consulting

Sanofi-Regeneron

Consulting
Teaching and Speaking
Leonard Calabrese, DO

Astra Zeneca, BMS

Teaching and Speaking

Novartis, Regeneron, Sanofi Aventis

Consulting

Genentech/Roche

Consulting
Advisor or review panel participant
Teaching and Speaking

Abbvie Pharmaceuticals, Janssen, UCB

Consulting
Teaching and Speaking
M. Elaine Husni, MD, MPH

Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb Co, Genzyme/Sanofi, Janssen, Lilly, Regeneron

Consulting
Advisor or review panel participant

Celgene Corporation, Pfizer, Inc.

Advisor or review panel participant

Genenetch, UCB, Inc.

Consulting

Novartis Pharmaceuticals

Consulting
Advisor or review panel participant
Teaching and Speaking

WebMD

Consulting
Teaching and Speaking
Elizabeth Kirchner, DNP

Janssen Pharmaceuticals, Inc.

Consulting

RhAPP

Teaching and Speaking

Boehringer Ingelheim, Horizon Pharma, UCB

Advisor or review panel participant
Carol Langford, MD

Astrazeneca Pharmaceuticals

Other activities from which remuneration is received or expected: Non-paid consultant for research Clinical trial funding support - this has ended

Bristol-Myers Squibb Co.

Other activities from which remuneration is received or expected: Clinical trial funding support Non- paid consultant for research

Chemocentryx, GlaxoSmithKline

Other activities from which remuneration is received or expected: Clinical trial funding support

Abbvie Pharmaceuticals

Other activities from which remuneration is received or expected: Non- paid consultant for research
Amanda Mixon, PA-C

Abbvie Pharmaceuticals

Consulting
Advisor or review panel participant
Teaching and Speaking

Eli Lilly, Janssen Pharmaceuticals, Inc

Advisor or review panel participant
Teaching and Speaking

Amgen

Teaching and Speaking

Astrazeneca Pharmaceuticals, RhAPP, Sanofi

Advisor or review panel participant

UCB, Inc.

Consulting
Zachary Wallace, MD

Bristol-Myers Squibb Co.

Research: PI

Horizon Pharma, Medpace, Zenas Biopharma

Consulting

Sanofi, Visterra, Inc

Consulting
Advisor or review panel participant

Novartis

Advisor or review panel participant

The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Marcela Ferrada, MD
Kinanah Yaseen, MD

Acknowledgment

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this live activity from: 

AbbVie, Inc.
Amgen, Inc.
AstraZeneca Pharmaceuticals
Bristol Myers Squibb
Genentech
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation
Pfizer, Inc. 

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this enduring activity from: 

AbbVie, Inc.
Amgen, Inc.
AstraZeneca Pharmaceuticals
Bristol Myers Squibb
Genentech
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation


This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s R.J Fasenmyer Center for Clinical Immunology.